Print

Purpose

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2). - Measurable multiple myeloma (MM). - Eastern Cooperative Oncology Group performance status of 0-1.

Exclusion Criteria

  • Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D). - Prior treatment with GPRC5D-targeting therapies. Note: Other protocol-defined inclusion/exclusion criteria apply

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A: BMS-986393 + Alnuctamab
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Alnuctamab
    Specified dose on specified days
    Other names:
    • BMS-986349
    • CC-93269
    • EM901
Experimental
Arm B: BMS-986393 + Mezigdomide
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Mezigdomide
    Specified dose on specified days
    Other names:
    • BMS-986348
    • CC-92480
Experimental
Arm C: BMS-986393 + Iberdomide
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Iberdomide
    Specified dose on specified days
    Other names:
    • BMS-986382
    • CC-220
Experimental
Arm D: BMS-986393 + Elranatamab
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Elranatamab
    Specified dose on specified days
    Other names:
    • Elrexfio

Recruiting Locations

University of Alabama at Birmingham
Birmingham 4049979, Alabama 4829764 35294-3300
Contact:
Susan Bal, Site 0008
205-934-1908

More Details

Status
Recruiting
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Study Contact

BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
Clinical.Trials@bms.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.